What this means
This is a planned study of a two-drug combination, GI-102 and GIB-7, in people. It has not reported results yet, so it cannot show whether the combination works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18–80
- Where
- 2 sites
The science
- Registered title
- A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors
- Trial ID
- NCT07363057 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Cancer Survivors, Healthy Participant, Elderly
- What is tested
- GI-102 in combination with GIB-7, Placebo
- Sponsor
- GI Innovation, Inc.
- Ages
- 18 Years to 80 Years
- Dates
- First posted Jan 23, 2026 · updated Jan 26, 2026
Registry summary
This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.
Sites (2)
- Novatrials, Charlestown, New South Wales, Australia
- Southern Oncology Clinical Research Unit, Adelaide, South Australia, Australia